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Angiogenesis is crucial for tumour growth and the formation of metastases. Various classes of angiogenesis inhibitors that are each
able to inhibit one of the various steps of this complex process can be distinguished. Results from clinical studies with these agents are
summarised. In general, it has been shown that most angiogenesis inhibitors can be safely administered, but that tumour regressions
are rare. Combining angiogenesis inhibitors with cytotoxic chemotherapy can enhance anticancer activity. Recently, some promising
data with regard to clinical efficacy have been presented. While performing clinical studies with angiogenesis inhibitors, defining
biological activity is crucial, but thus far no validated techniques are available. It is conceivable that in the near future various classes of
angiogenesis inhibitors will be combined in an attempt to further improve antiangiogenic and anticancer activity.
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In order to grow and metastasise, tumours exceeding the size of
1mm
3 are dependent on blood supply from newly formed adjacent
blood vessels.
Tumour-related angiogenesis is a multistep process that is
initiated through the activity of various proangiogenic factors or
stimuli that are secreted by tumour cells and host components such
as macrophages, lymphocytes and kidney cells (Klagsbrun and D’
Amore, 1996). Of these proangiogenic factors, vascular endothelial
growth factor (VEGF) is predominant. Vascular endothelial growth
factor binds with high affinity to the transmembrane endothelial
VEGF receptor type 1 and 2 (VEGFR-1 or flt-1 and VEGFR-2 or
FLK-1/KDR, respectively). Ligand–receptor interaction initiates a
cascade of intracellular signals through increased receptor tyrosine
kinase activity, resulting in endothelial cell proliferation and the
formation of new blood vessels. Increased expression of VEGF is
associated with poor clinical outcome irrespective of tumour stage
or tumour grade.
Besides VEGF, basic fibroblast growth factor (bFGF), platelet-
derived growth factor (PDGF), interleukin-8 and insulin-like
growth factor (IGF) are factors involved in angiogenesis, and
these factors have their own endothelial cell receptors.
As angiogenesis is of crucial importance for tumour growth,
inhibiting this process has become a major challenge in the
development of new anticancer agents.
Tumour-related angiogenesis is dependent on specific growth
factors, the presence and activation of endothelial cell receptors,
endothelial cell proliferative activity as such, and the interaction
between proliferating endothelial cells and extracellular matrix
components. All these specific steps can be inhibited by targeted
agents.
Neutralising VEGF prior to its attachment to endothelial receptors
can be accomplished by monoclonal antibodies. Inhibiting the
tyrosine kinase activity of VEGFR-2, PDGF and/or bFGF receptors
following ligand binding can be achieved through specific inhibitors.
Inhibiting endothelial cell proliferation can be achieved by mimick-
ing the activity of naturally occurring antiangiogenic proteins such
as thrombospondin-1 (TSP-1), endostatin and angiostatin. Inhibiting
the interaction between proliferating endothelial cells and various
extracellular matrix components can be accomplished by inhibiting
the activity of the transmembrane endothelial cell integrins avb3a n d
avb5. In contrast to quiescent blood vessels where expression of
integins is minimal, actively proliferating endothelial cells express
integrins to a high extent. Integrin activity can be inhibited by
antibodies or small molecule inhibitors.
A different approach that may lead to diminished tumour
vascularisation is the destruction of established vasculature. The
so-called ligand-directed vascular targeting agents (VTAs) are able
to induce a rapid and specific shutdown of tumour blood supply
either by using antibodies, peptides or growth factors that deliver
toxins and procoagulants or apoptotic effectors specifically to the
tumour endothelium. The so-called small-molecule VTAs try to
recognise the pathophysiological differences between the normal
and tumour endothelium, and are thus able to induce vascular
shutdown, specifically in tumours.
In this review, we will give an overview of the results of clinical
studies that have been performed with various classes of
antiangiogenic and antivascular agents (Table 1). While discussing
the results of these studies, we will focus in more detail on the
mechanisms of action, and we will discuss some of the difficulties
that have been faced while performing these studies. Finally, we
will give some thoughts on where to go in future studies.
WHERE ARE WE NOW?
Monoclonal antibodies directed against VEGF
Bevacizumab is a humanised monoclonal VEGF antibody with
antiangiogenic and antitumour activity in preclinical models.
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tion schedules showed that the agent, given as single agent or in
combination with various cytotoxic agents, was safe and did not
cause dose-limiting toxicity (DLT) when given at predefined doses.
Some bleeding episodes were seen that were not attributed to the
agent. Antiangiogenic activity was assessed by contrast-enhanced
dynamic magnetic resonance imaging (DEMRI), showing a
decrease in tumour microvascular permeability. Biological activity
was also demonstrated by a decline in serum levels of unbound
VEGF (Gordon et al, 2001; Margolin et al, 2001; Langmuir et al,
2002).
Phase II studies in patients with various tumour types showed
partial tumour regressions and/or increased time to progression
(compared to placebo or cytotoxic treatment alone), when
bevacizumab was given in various doses and different dosing
intervals, either as single agent or in combination with various
cytotoxic agents. In these studies, the increased incidence of
thromboembolic complications, bleeding episodes (some of which
were lethal), hypertension and proteinuria was the reason for
concern (Burnstein et al, 2002; Miller et al, 2002; Yang et al, 2002;
Kabbinavar et al, 2003). Two randomised phase III studies
combining bevacizumab with standard cytotoxic treatment in
patients with metastatic breast cancer showed disappointing
results (Miller et al, 2002, 2003), but a recently presented
randomised phase III study in 800 previously untreated patients
with metastatic colorectal cancer comparing treatment with
irinotecan, 5-fluorouracil and leucovorin (IFL) and IFL combined
with bevacizumab given every 2 weeks showed increased response
rates, prolonged time to progression and significantly increased
survival with no increased incidence of thromboembolic compli-
cations (Hurwitz et al, 2003).
VEGF-trap is a specific antagonist that binds to and subse-
quently inactivates VEGF. It is claimed to have a higher affinity for
VEGF than monoclonal antibodies, and can be administered
subcutaneously. Phase I studies are ongoing (Dupont et al, 2003).
VEGFR-2 antibodies
As ligand–receptor interaction of VEGF and VEGFR-2 is crucial
for endothelial proliferation, it is conceivable that apart from
blocking VEGF as the principal ligand, blocking VEGFR-2 is
another rational approach to prevent this cascade. However,
monoclonal antibodies targeting VEGFR-2 have not yet been tested
extensively and, to date, only one phase I study with such a
compound, IMC-1C11, has been published. No major drug-related
toxicity was seen in this small study (Posey et al, 2003).
VEGF receptor tyrosine kinase inhibitors
SU5416 showed antiangiogenic and antitumour activity in
preclinical studies, and was the first VEGF receptor tyrosine
kinase inhibitor to be tested clinically (Stopeck et al, 2003).
Phase I trials yielded headache and vomiting as DLT. Due to a
short half-life, SU5416 had to be given frequently in order to
achieve active plasma concentrations for prolonged periods of
time. The twice-weekly treatment schedule was studied most often,
but even this schedule yielded active plasma concentrations for
only a limited period of time. A more frequent intravenous
administration schedule was considered to be unpractical, and
limited bioavailability hampered the development of an oral
compound. Although some clinical activity was recorded, and
DEMRI analysis revealed a reduction in tumour vascular
Table 1 Angiogenesis inhibitors in clinical trials
Drug Company Target Clinical development
Monoclonal antibodies targeting VEGF-A
Bevacizumab (Avastin
s) Genentech VEGF-A Phase I, II, III
VEGF-Trap Regeneron VEGF-A Phase I
Antibodies targeting VEGFR-2
IMC-1C11 Imclone VEGFR-2 Phase I
Receptor tyrosine kinase inhibitors
SU5416 Sugen/Pharmacia VEGFR-2 Phase I, II, III
SU6668 Sugen/Pharmacia VEGFR-2, bFGFR, PDGFR Phase I, II
SU11248 Sugen/Pharmacia VEGFR-2, PDGFR,
c-Kit, Flt-3 Phase I
PTK787/ZK22854 Schering/Novartis VEGFR-1, VEGFR-2 Phase I
ZD6474 Astra Zeneca VEGFR-2, EGFR Phase I, II
CP-547,632 Pfizer VEGFR-2, EGFR, PDGFR Phase I
Inhibitors of endothelial cell proliferation
ABT-510 Abbott Endothelial CD-36 Phase I, II
Angiostatin Entremed Various Phase I
Endostatin Entremed Various Phase I
TNP-470 TAP Methionine aminopeptidase, cyclin dependent kinase 2 Phase I
Thalidomide Grunenthal Reduction of TNF-a production Phase I, II, III
Inhibitors of integrin activity
Vitaxin MedImmune Integrin aVb3 Phase I, II
Medi-522 MedImmune Integrin aVb3 Phase I
Cilengitide Merck KgaA Integrin aVb3 Phase I
Vascular targeting agents
Combretastatin A4 Oxigene Endothelial tubulin Phase I
AVE8062A Aventis Endothelial tubulin Phase I
ZD6126 Astra Zeneca Endothelial tubulin Phase I
DMXAA Induction of TNF-a Phase I
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means of consistent changes in the serum markers of endothelial
cell proliferation. In phase I and II combination trials, SU5416
could be given safely in combination with 5-FU and leucovorin,
but combining SU5416 with cisplatinum and gemcitabine yielded
an unexpectedly high number of severe thromboembolic compli-
cations, leading to premature closing of the study (Kuenen et al,
2002a). Randomised phase III studies of SU5416 with 5-FU/
leucovorin and 5-FU/leucovorin/irinotecan in patients with meta-
static colorectal carcinoma failed to show a survival benefit of the
SU5416 containing regimens, resulting in the cessation of further
development of this compound.
SU 6668 is an orally available inhibitor of VEGF, bFGF and
PDGF receptor tyrosine kinase activity. Phase I trials showed good
tolerability with once daily dosing, but a twice daily administration
schedule yielded DLT consisting of fatigue, dyspnea, chest pain
and pericardial effusions (Rosen et al, 2001; Brahmer et al, 2002).
Pharmacokinetic analysis revealed a short plasma half-life, with
plasma concentrations exceeding those that inhibited tyrosine
kinase activity in preclinical models in the first day, but not
following prolonged administration. Due to these disappointing
results, and despite the fact that some clinical activity was noted in
clinical studies, the compound was withdrawn from further
development (Britten et al, 2002; Kuenen et al, 2002b; Ueda et al,
2002).
SU11248 is a broad-spectrum orally available tyrosine kinase
inhibitor, inhibiting VEGF, PDGF, c-Kit and Flt-3 kinase activity
(Mendel et al, 2002). This inhibitory spectrum makes this agent to
be more than a specific antiangiogenic agent. The recently
presented phase I trials exploring either 14 or 28 days treatment
followed by 14 days off treatment yielded DLT consisting of
fatigue, lethargy and myelosuppression. Two patients died due to
drug-related neutropenic sepsis. Tumour regressions have been
noted, and positron emission tomography (PET) imaging studies
and a rise in serum VEGF levels parallelled by a consistent
decrease in soluble VEGFR-2 levels indicate antiangiogenic activity
(Manning et al, 2003; Raymond et al, 2003; Rosen et al, 2003;
Toner et al, 2003). Phase II trials are being initiated.
PTK787/ZK22854 is an orally available VEGFR-1 and VEGFR-2
tyrosine kinase inhibitor. Ataxia, vertigo and hypertension were
noted as DLTs, whereas some cases of venous thromboembolism
were recorded (Yung et al, 2002). Biological activity has been
demonstrated as DEMRI analysis showed a dose-dependent
decrease in blood flow in hepatic metastases of colorectal cancer
patients (Thomas et al, 2001; Drevs et al, 2002; Yung et al, 2003).
Phase II and III trials with PTK in combination with 5-fluorouracil,
irinotecan and/or oxaliplatin in patients with metastatic colorectal
cancer have been performed or are currently ongoing (Steward
et al, 2003; Trarbach et al, 2003).
ZD6474 inhibits both VEGF and epidermal growth factor (EGF)
receptor tyrosine kinase activity. Following prolonged continuous
oral administration, DLT consisted of diarrhoea, hypertension,
hepatic toxicity and cutaneous rash, whereas asymptomatic QTc
prolongation was seen throughout the dose levels studied (Hurwitz
et al, 2002; Minami et al, 2003). Hints of clinical activity were
recorded in some patients. It is conceivable that diarrhoea and skin
rash are due to the inhibition of the EGF receptor tyrosine kinase
activity, illustrating the broad range of tyrosine kinase inhibition
by this agent.
CP-547,632 is a selective VEGFR-2 receptor tyrosine kinase
inhibitor that is currently in phase I studies (Tolcher et al, 2002).
Naturally occurring inhibitors of endothelial cell
proliferation
Thrombospondin-1 is a naturally occurring inhibitor of endothelial
cell proliferation. As TSP-1 is a large protein, restricting its
pharmacological use, and as its antiangiogenic effects are restricted
to the N-terminal region, various structural modifications have
been made, leading to TSP-1 mimetic proteins. ABT-510 is such a
protein that can be administered subcutaneously. Phase I studies
have shown excellent tolerability at all dose levels tested, also
following prolonged administration (De Vos et al, 2002; Gordon
et al, 2003). Pharmacokinetic analysis has shown that plasma
concentrations exceeding those inhibiting angiogenesis in pre-
clinical studies could be maintained for prolonged periods of time
following once or twice daily administration. Phase I combination
studies are ongoing, whereas single-agent phase II studies in
NSCLC and renal carcinoma have been initiated.
Endostatin and angiostatin are both naturally occurring
angiogenesis inhibitors that are able to induce the apoptosis of
endothelial cells and to inhibit endothelial cell migration and
proliferation. Endostatin is a 20kDa fragment derived from the C-
terminal region of collagen XVIII, angiostatin is a 38kDa fragment
of plasminogen. Various mechanisms of action are considered for
these antiangiogenic properties.
Phase I studies with recombinant human endostatin given as
daily i.v. bolus injections revealed no drug-related toxicity and
some hints of clinical activity. The pharmacokinetic analyses
showed that, at the highest dose that could be practically
administered, drug exposure was lower than that yielding
maximum tumour growth inhibition in preclinical studies.
Additionally, DEMRI analysis done in a number of patients did
not show any relevant changes in perfusion throughout the
treatment period (Eder et al, 2002) and analysis of various serum
markers of angiogenesis was inconclusive (Herbst et al, 2002).
Currently, studies exploring continuous intravenous and subcuta-
neous administration of endostatin are being performed, with
preliminary data showing increased drug exposure when com-
pared to bolus administration (Hansma et al, 2002; Tran et al,
2002).
Angiostatin is currently undergoing phase I clinical trials,
exploring both i.v. and twice daily subcutaneous injections
(Beerepoot et al, 2001; DeMoraes et al, 2001; Voest et al, 2002).
Other inhibitors of endothelial cell proliferation
TNP-470 is a derivative of the natural compound fumagilin that
showed antiangiogenic activity in preclinical models through
inhibition of cyclin-dependent kinase 2, retinoblastoma protein
phosphorylation and methionine aminopeptidase.
The first clinical studies with TNP-470 explored weekly 1-h
infusions, but as the terminal plasma half-life turned out to be only
minutes, additional studies with either more frequent administra-
tions or more protracted infusion schedules (up 120h) were
performed. Dose-limiting toxicity consisted of neuropsychiatric
effects (Bhargava et al, 1999; Stadler et al, 1999; Logothetis et al,
2001). More recently, TNP-470 administered as a protracted
infusion in combination with paclitaxel and carboplatin has
yielded interesting efficacy data in patients with NSCLC (Blu-
menschein et al, 2002).
Although the exact mechanism of antiangiogenic action of
thalidomide has not been fully elucidated, a large number of
clinical studies with this compound have been performed. In
particular, patients with multiple myeloma seem to benefit from
thalidomide, although some responses have also been recorded in
solid tumours. Obstipation, lethargy and peripheral neuropathy
have been ascribed to thalidomide.
Vitaxin is a monoclonal antibody of the integrin avb3 that can
be administered subcutaneously. A phase I trial showed good
clinical tolerability and antitumour activity in a patient with
leiomyosarcoma. Direct antiangiogenic activity was not demon-
strated (Gutheil et al, 2000). A phase II study in patients with
leiomyosarcomas did not confirm antitumour activity (Patel et al,
2001).
Angiogenesis inhibitors in clinical development
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the integrin avb3 receptor that is currently undergoing phase I
studies (Faivre et al, 2003).
Cilengitide is a small molecule inhibitor of the integrins avb3
and avb5. A phase I study exploring a continuous twice weekly i.v.
administration schedule showed excellent clinical tolerability with
no drug-related side effects following a predefined dose escalation
schedule (Eskens et al, 2003). Pharmacokinetic analysis demon-
strated that plasma concentrations exceeding those that yielded
optimal antiangiogenic activity in preclinical models were reached.
Currently, aditional pharmacodynamic analysis to explore biolo-
gical activity is being done (Holden et al, 2002).
Vascular targeting agents
Combretastatin prodrug A4 (CA4P) is a tubulin-depolymerising
VTA that is able to induce a rapid change in endothelial cell shape,
causing a disruption of the endothelial layer, vascular congestion
and loss of blood flow. Preclinical studies showed selectivity for
rapidly proliferating tumour endothelium, leaving mature en-
dothelial cells unaffected. Dose-limiting toxicity in three phase I
studies, exploring different treatment schedules, consisted of acute
coronary syndrome, tumour pain and ataxia. QTc prolongation,
cutaneous flushing and hot flashes and diffuse abdominal pain and
tumour pain were associated with the drug infusion. One
pathological complete response lasting 33 months was recorded
in a patient with an anaplastic thyroid carcinoma.
Reversible decreases of tumour blood flow were observed using
either dynamic enhanced MRI scanning or PET scanning
(Stevenson et al, 2000; Rustin et al, 2001; Dowlati et al, 2002).
AVE8062A is a combretastatin analogue that is undergoing
phase I testing. Transient and reversible myocardial and central
nervous system ischaemia were recorded at the highest dose levels
studied (Tolcher et al, 2003).
ZD6126 binds to endothelial tubulin, and is able to induce
changes in endothelial shape, leading to vascular shutdown.
Preclinical studies showed that only immature endothelial cells
responded to ZD6126, whereas mature endothelial cells were not
affected.
In a phase I study exploring a 10-min single i.v. administration
once every 21 days, abdominal pain and gastrointestinal toxicity
were dose limiting. Significant changes in tumour blood flow
were observed, as some cases of prolonged stable disease
(DelProposto et al, 2002; Gadgeel et al, 2002). A second phase I
study is exploring a weekly administration schedule (Radema et al,
2002).
DMXAA is a flavonoid that, in preclinical models, is able to
induce TNF-a production and induce vascular disruption,
selectively in the tumour microenvironment.
In a phase I trial, DLT consisted of urinary incontinence, various
seemingly central nervous system-related toxicities, dyspnea and
cardiac toxicity (Rustin et al, 2003).
Biological activity was assessed by means of DEMRI analysis,
showing changes in tissue perfusion, vessel permeability and vessel
surface area (Galbraith et al, 2002).
WHERE ARE WE GOING?
The first clinical studies with antiangiogenic agents were initiated 5
years ago, when preclinical studies in mice showed tumour
disappearance and prolonged survival following the administra-
tion of endostatin and angiostatin. Scientists and especially the lay
press were excited over these results.
Clinical studies of these 5 years have shown that many
angiogenesis inhibitors can be given safely to patients. Some
antiangiogenic agents were even completely devoid of toxicity, and
defining an optimal dose for subsequent activity testing of these
agents was difficult, if not impossible. In the meantime, it became
obvious that antiangiogenic activity of some agents occurred at
very low doses, even more questioning the concept of dose
escalation until toxicity. Determining optimal biological activity
became an important new end point in phase I studies.
How can we optimally define the optimal biologically effective
dose, and which pharmacodynamic analysis should be used for
this?
Target inhibition, dormancy of endothelial cells or vascular
shutdown with subsequent tumour ischaemia are important
biologial end points that have the potential to predict antitumour
activity, but the only reliable source to determine these end points
is the tumour. Here we are facing practical problems, because most
physicians consider taking repeated tumour biopsies to be very
cumbersome for patients. Although some authors consider taking
these biopsies repeatedly to be feasible (Dowlati et al, 2001), the
number of studies incorporating these procedures is still small.
Although many alternative procedures and strategies have been
developed to circumvent this problem, it is conceivable that, in
future studies, exploring antiangiogenic agents taking tumour
biopsies will become mandatory.
While trying to demonstrate biological activity in a less invasive
manner, various surrogate markers of antiangiogenic or anti-
vascular activity have been studied. The analysis of serum markers
of endothelial cell proliferation thus far has failed to show
consistent changes following treatment with most antiangiogenic
agents, but changes in serum concentrations of VEGF and soluble
VEGFR-2 seem to have more potential to predict tumour hypoxia
(Drevs et al, 2003; Toner et al, 2003). The pathophysiological
mechanisms that explain these changes are still a matter of debate,
however, as tumour hypoxia as such has not been demonstrated in
human tumours.
Noninvasive techniques such as DEMRI and PET scans are
increasingly used to demonstrate the biological activity of
antiangiogenic agents or VTAs. These techniques can show
changes in tumour blood flow and tumour viability, respectively.
In numerous studies, DEMRI and PET scan studies were able to
demonstrate these pharmacodynamic effects, but it must be
realised that both techniques are still unvalidated to predict
antitumour activity or patient benefit. Only large clinical studies
correlating the outcomes of DEMRI and PET scan studies with
clinical outcome can definitely assess the role of these techniques
in future patient management.
Another method to assess the biological activity of antiangio-
genic agents is by the use of pharmacokinetic studies. Drug
exposure or peak plasma concentrations can be used to determine
the dose that is most likely to give antiangiogenic or antitumour
activity, but here it has to be realised that comparing human
plasma concentrations to target inhibitory concentrations in
preclinical models cannot and will not always be predictive for
the same biological effect. Nevertheless, pharmacokinetic analysis
will remain of crucial importance to prevent unnecessary dose
escalation in case of incomplete or saturated absorption with
maximal drug exposure, and to show the relations between clinical
toxicity and plasma concentrations.
Antiangiogenic agents are cytostatic agents that are not likely to
cause tumour regressions in patients with advanced or metastatic
cancer. In order to assess their antitumour activity in phase II
studies, combining these agents with cytotoxic anticancer agents
seems to be a logical step. Clinically, the combination of two
antiangiogenic agents, each having a distinctive inhibitory
mechanism of action, has not been tested thus far. A large number
of studies combining cytotoxic and antiangiogenic agents have
been performed. These phase II studies most often had a
randomised design, comparing the response rates or time to
disease progression. In order to define safe combination dosages,
these studies were always preceded by phase I combination studies
showing the safety of these combinations.
Angiogenesis inhibitors in clinical development
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demonstrate improved antitumour activity of the combination
treatment, results of large randomised phase III trials were eagerly
awaited. However, until recently, these phase III trials, mostly done
in patients with metastatic colorectal or breast cancer, all failed to
show improved survival, and serious concern was growing as to
whether we would ever be able to demonstrate the clinical efficacy
of any of these exciting and promising agents.
It was with great excitement, therefore, that recently the first
randomised phase III trial in patients with metastatic colorectal
cancer showed improved survival when cytotoxic treatment was
combined with bevacizumab. It is this trial that, on the one hand,
has reconfirmed the conviction that we, currently, are testing
effective new agents, whereas, on the other hand, it has become
clear that the only way to assess clinical benefit or a complete
generation of these agents will be through these large, costly and
time-consuming randomised trials. Besides, we have to accept that
more than one randomised trial will be needed, as at this moment
it is not even fully clear that the dose tested in this study is in fact
the most optimal one. Another intriguing question that remains is
why the addition of bevacizumab was beneficial to this group of
colorectal carcinoma patients, whereas results of randomised
studies with various other antiangiogenic agents in a comparable
population of patients all turned out to be negative.
If one is to consider the currently perceived limited antitumour
activity of single-agent antiangiogenic treatment, it can be argued
that a combination of antiangiogenic agents with different targets
or a combination of antiangiogenic agents and VTAs might show
increased activity. Preclinical studies exploring such combinations
are now being performed, and some promising data have been
presented. In addition to this, it is also conceivable that combining
antiangiogenic agents with other targeted agents should be
explored, but for this the help of pharmaceutical companies who
are willing to share their compounds and knowledge is urgently
needed.
If one is still to explore single agent antiangiogenic treatment, a
situation of minimal residual disease following either cytoreduc-
tive surgery or cytotoxic treatment seems most appropriate to
adequately assess the role of these agents in secondary cancer
growth prevention. These adjuvant studies will, by their design,
definitely be time and patient consuming, and here an important
as yet unanswered question is that of patient convenience and
optimal duration of treatment.
In conclusion, 5 years of clinical studies with antiangiogenic
agents have yielded promising results, and therefore antiangio-
genic agents have the potential to play a role as active anticancer
agents. To definitely confirm this role, specifically designed phase I
studies, using the correct end points, must be able to define one or
more safe and biologically active doses that can be tested in
properly designed randomised phase II trials. Here, a wide array of
possible combinations can be thought of. Finally, it is mandatory
that in more than one randomised phase III trial patient benefit is
demonstrated.
The role of the VTAs is not yet established as only phase I
studies have been performed so far, but considering their
mechanism of action, more studies will definitely follow.
After a period of flawing interest, antiangiogenic agents have
regained their place in the centre of investigational antitumour
treatment, and it is without any doubt that in the future their role
in clinical practice will be established.
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